Summary of Key Information:

Reporting Period (Quarter/Year): Quarter and Half Year ended September 30, 2026 (Q2 FY27)

Nature of Filing / Announcement: Regulatory filing of unaudited financial results pursuant to SEBI Listing Regulations 33 and 30

Audit Opinion:

Clean, unmodified review opinion. Walker Chandiok & Co LLP stated: "Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement... contains any material misstatement."

Auditor’s Comment:

No qualifications or modifications affecting earnings quality, internal controls, or going concern.

Key Financial Highlights [₹ in million]:

Standalone Results:

Quarter Ended September 30, 2026:

  • Revenue from Operations: ₹685 (vs ₹664 in Q2 FY26; ₹671 in Q1 FY27)
  • Total Income: ₹694
  • Net Profit from Continuing Operations: ₹76 (vs loss of ₹1,480 in Q2 FY26; ₹73 in Q1 FY27)
  • EPS (Basic) from Continuing Operations: ₹0.48

Half Year Ended September 30, 2026:

  • Revenue from Operations: ₹1,356 (vs ₹1,259 in H1 FY26)
  • Total Income: ₹1,366
  • Net Profit from Continuing Operations: ₹149 (vs loss of ₹1,439 in H1 FY26)
  • EPS (Basic) from Continuing Operations: ₹0.94

Standalone Balance Sheet as at September 30, 2026:

  • Cash and Cash Equivalents: ₹158
  • Total Debt (Borrowings): ₹953 (Current ₹453 + Non-current ₹500)
  • Other Equity: ₹22,409
  • Total Assets: ₹24,576

Consolidated Results:

Quarter Ended September 30, 2026:

  • Revenue from Operations: ₹23,700 (vs ₹19,664 in Q2 FY26; ₹22,294 in Q1 FY27)
  • Total Income: ₹23,844
  • Net Profit: ₹310 (vs ₹1,199 in Q2 FY26; ₹564 in Q1 FY27)
  • EPS (Basic): ₹1.97

Half Year Ended September 30, 2026:

  • Revenue from Operations: ₹45,994 (vs ₹38,671 in H1 FY26)
  • Total Income: ₹46,337
  • Net Profit: ₹874 (vs ₹2,224 in H1 FY26)
  • EPS (Basic): ₹5.54

Consolidated Balance Sheet as at September 30, 2026:

  • Cash and Cash Equivalents: ₹12,198
  • Total Debt (Borrowings): ₹38,922 (Current ₹4,590 + Non-current ₹34,332)
  • Other Equity: ₹71,386
  • Total Assets: ₹166,646

Segment-wise Performance [₹ in million]:

Quarter Ended September 30, 2026 Segment Revenue:

  • Radiopharma: ₹10,093
  • Allergy Immunotherapy: ₹2,295
  • Contract Development and Manufacturing Organisation - Sterile Injectables: ₹5,596
  • Contract Research, Development and Manufacturing Organisation: ₹3,448
  • Generics: ₹2,741
  • Proprietary Novel Drugs: Not specified

Quarter Ended September 30, 2026 Segment Results (Profit/Loss before tax, exceptional items and interest):

  • Radiopharma: Profit ₹698
  • Allergy Immunotherapy: Profit ₹657
  • Contract Development and Manufacturing Organisation - Sterile Injectables: Loss ₹42
  • Contract Research, Development and Manufacturing Organisation: Profit ₹200
  • Generics: Profit ₹51
  • Proprietary Novel Drugs: Loss ₹102

Corporate Actions:

  • The Board on October 12, 2026, approved issuance of up to 80,000 non-convertible debentures (NCDs) of face value ₹100,000 each, aggregating ₹8,000 million on a private placement basis.
  • On November 5, 2026, the Company allotted unsecured NCDs aggregating ₹8,000 million to successful bidders.
  • No dividend declared in this announcement.

Other Significant Information:

  • The consolidated entity includes 40 subsidiaries as listed in Annexure 1.
  • Previous period figures have been regrouped/reclassified to conform to current period's classification.